TLDR
- NVIDIA dominates AI chip market with 35%+ annual EPS growth forecast and 39 analyst buy ratings, powering data centers and autonomous vehicle technology
- Amazon Web Services drives 60% of company profits with 25% projected yearly revenue growth, earning Buy or Strong Buy ratings from 45 analysts
- Microsoft’s Azure cloud platform and OpenAI partnership support 18% EPS growth projections with unanimous buy ratings from 33 analysts
- CRISPR Therapeutics’ Casgevy gene therapy treats blood disorders with 50%+ EPS growth potential, though clinical risks lead to mixed analyst views
- Viking Therapeutics’ oral weight-loss drug VK2735 shows promise in $100B+ obesity market with 60%+ EPS growth and 14 Strong Buy ratings
Wall Street analysts have issued positive ratings for five companies across technology and healthcare industries. The firms operate in artificial intelligence, cloud infrastructure, gene editing, and obesity treatment markets. Projected earnings per share growth ranges from 18% to 60% annually over the next five years.
These stocks include three large-cap technology companies and two mid-cap healthcare firms. Each company holds a leadership position in its respective market segment. Analyst consensus ratings reflect confidence in their growth trajectories through 2030.
NVIDIA Corporation Shows AI Chip Dominance
NVIDIA manufactures semiconductors for artificial intelligence applications. The company’s graphics processing units power data centers, machine learning systems, and autonomous vehicle platforms. Demand for AI infrastructure has driven increased orders from tech companies and research institutions.
NVIDIA Corporation, NVDA
Analysts forecast 35% or higher annual earnings per share growth for NVIDIA through 2030. This projection is based on expanding AI adoption across multiple industries. The company’s chips are essential components in training large language models and running AI workloads.
Among 39 analysts covering NVIDIA, 39 issue buy ratings. One analyst rates the stock hold and one recommends selling. The overwhelming buy consensus reflects confidence in the company’s market position.
Trade policy changes occasionally impact NVIDIA’s stock price. However, the company maintains its position as the primary supplier of AI chips to major technology firms.
Amazon Web Services Powers Company Growth
Amazon operates e-commerce, cloud computing, and digital advertising businesses. Amazon Web Services generates over 60% of the company’s total profits. The cloud division provides infrastructure services to corporations and government agencies worldwide.
Amazon.com, Inc., AMZN
AWS revenue is expected to grow 25% annually through artificial intelligence service integration. The division offers machine learning tools, data storage, and computing power to enterprise clients. Amazon’s retail operations provide additional revenue stability.
Out of 45 analysts, 47% rate Amazon Strong Buy and 51% rate it Buy. Just 2% of analysts give the stock a Hold rating. No analysts recommend selling Amazon shares.
The company’s advertising business has grown as more brands shift spending to digital platforms. This diversification across multiple revenue streams supports analyst confidence in Amazon’s long-term prospects.
Microsoft Expands Cloud and AI Services
Microsoft Corporation operates the Azure cloud platform and maintains an enterprise software portfolio. The company has partnered with OpenAI to integrate AI capabilities into its products. Office 365, Teams, and other subscription services generate recurring revenue from corporate customers.
Microsoft Corporation, MSFT
Analysts project 18% annual earnings per share growth for Microsoft. This forecast is based on increasing demand for cloud infrastructure and productivity software. The company’s products work together in an integrated ecosystem that makes switching to competitors difficult.
All 33 analysts covering Microsoft issue buy ratings. Two analysts rate the stock hold. No analysts recommend selling Microsoft shares.
Azure competes with Amazon Web Services and Google Cloud for enterprise customers. Microsoft’s existing relationships with corporations give it an advantage in selling cloud services. Analysts see untapped revenue potential from AI-powered features in Microsoft’s software products.
CRISPR Therapeutics Advances Gene Editing Treatments
CRISPR Therapeutics develops gene therapies for genetic diseases. The company’s Casgevy treatment has received approval for sickle cell disease and beta-thalassemia. Additional pipeline programs target cancer, diabetes, and other conditions.
Analysts project potential earnings per share growth exceeding 50% for CRISPR. This forecast depends on securing additional regulatory approvals for pipeline drugs. The gene therapy market could expand significantly as more treatments become available.
Among 17 analysts, 35% rate CRISPR Strong Buy and 24% rate it Buy. However, 35% of analysts rate the stock Hold and 6% recommend selling. The mixed ratings reflect uncertainty around clinical trial outcomes and approval timelines.
Gene therapy represents a new treatment approach for previously incurable diseases. CRISPR’s technology allows for precise genetic modifications in patient cells. Regulatory agencies have approved the first CRISPR-based treatments after years of clinical testing.
The company faces competition from other gene therapy developers. Clinical trial results and manufacturing capabilities will determine CRISPR’s ability to bring additional treatments to market.
Viking Therapeutics Develops Obesity Medications
Viking Therapeutics focuses on metabolic diseases including obesity. The company’s VK2735 candidate is an oral weight-loss drug currently in clinical trials. Phase 2 trial results showed weight reduction comparable to injectable GLP-1 medications like Ozempic.
The global obesity treatment market exceeds $100 billion in annual sales. Analysts project earnings per share growth above 60% for Viking based on potential drug approvals and partnership deals. The oral delivery method differentiates VK2735 from existing injectable treatments.
Fourteen analysts cover Viking Therapeutics. Half rate the stock Strong Buy, 36% rate it Buy, and 14% rate it Hold. No analysts recommend selling Viking shares.
Pharmaceutical companies have shown interest in obesity drugs following the success of Wegovy and Ozempic. Viking’s oral formulation could appeal to patients who prefer not to use injections. The company will need to complete Phase 3 trials before seeking regulatory approval.
Clinical trial success rates vary in drug development. Viking must demonstrate both safety and effectiveness in larger patient populations. Partnerships with major pharmaceutical companies could accelerate development and commercialization.
Summary
The five stocks have received majority buy ratings from analysts as of December 2025. Technology companies NVIDIA, Amazon, and Microsoft represent established firms with proven business models. Healthcare companies CRISPR Therapeutics and Viking Therapeutics are developing newer treatments with higher risk profiles.
The post Top Growth Stocks to Buy Today appeared first on Blockonomi.
Source: https://blockonomi.com/top-growth-stocks-to-buy-today/